Paul Howe, chief commercial officer at Protega, discusses efforts to combine high tech solutions with pain-management medications.

Trial findings show long-term recurrence-free survival in patients with low-grade upper tract urothelial cancer treated with ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in ...

Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...

The trial, developed in collaboration with Novotech, will specifically target dietary and alcohol-induced overindulgence.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Viralgen and Axovia Therapeutics are partnering to develop and manufacture a gene therapy for the treatment of retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic ...

PharmaScroll announced a new generative AI chatbot called Self-Serve AI. 1 The company describes it as a research and ...

The two organizations will produce educational materials about the medicine and its importance for people living with type 1 ...

Expanded GTM services aim to ensure members receive tests at the optimal times while cutting down on testing misuse.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...